Comparable stake leader
Iris Acquisition Holdings LLC
SEC ownership of Liminatus Pharma, Inc.
Top holders, 13D/G large-stake signals, insider positions, and transaction flow tied to CIK 0001971387.
Disclosed value leader
Valetudo Therapeutics LLC
Comparable rows
20/42
Latest evidence
02 Jul 2026
- Public ticker
- LIMN, LIMNW on Nasdaq
- Parsed ownership sources
-
3/4/5, 13D/G, and 13F
Source: Parsed SEC ownership filingsUse: Compare filing families carefully
- Largest SEC-reported holder
-
Iris Acquisition Holdings LLC
Ranking: Comparable ownership first, then disclosed value
- Comparable ownership rows
-
20 of 42
Meaning: Rows with safely comparable ownership %
- Latest 13D/G holder
-
Iris Acquisition Holdings LLC
Source: Latest parsed Schedule 13D/G stake
- Latest parsed ownership date
-
02 Jul 2026
Freshness: Most recent filing date in this holder set
- Issuer CIK
- 0001971387
- Issuer location
- Cerritos, CA
Ownership snapshot
CIK-linked ownership evidence from parsed SEC filings.
3 signals
Issuer
Names, identifiers, and filing context for this profile.
2 identity fields
Ownership snapshot
Top shareholders of Liminatus Pharma, Inc. (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
Iris Acquisition Holdings...
Disclosed value leader
Valetudo Therapeutics LLC
Comparable rows
20/42
Latest evidence
02 Jul 2026
3/4/5
13D/G
13F
Lead comparable stake: 26%
22 rows are not safely comparable across share classes.
13D/G row: Iris Acquisition Holdings LLC
Showing 1-8 of 42 holder rows.
Quick read
Iris Acquisition Holdings LLC leads the comparable SEC ownership view at 26%.
20 of 42 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens Iris Acquisition Holdings LLC's linked filing trail.
Comparable ownership
Top 5
Iris Acquisition Holdings LLC
26%
KH Feelux Co., Ltd
15%
Valetudo Therapeutics LLC
14%
Ewon Comfortech Co., Ltd.
11%
Apple Association 1st Nongae
5.7%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-8 of 42 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| Iris Acquisition Holdings LLC |
3/4/5
13D/G
10%+ Owner
|
26%
from 13D/G
|
$45,885,000
6,900,000 shares
|
— | 30 Apr 2025 |
| KH Feelux Co., Ltd |
3/4/5
13D/G
10%+ Owner
|
15%
from 13D/G
|
$20,880,000
4,000,000 shares
|
— | 30 Apr 2025 |
| Valetudo Therapeutics LLC |
3/4/5
13D/G
10%+ Owner
|
14%
from 13D/G
|
$69,466,653
5,293,326 shares
mixed-class rows
|
— | 02 Jul 2026 |
| Ewon Comfortech Co., Ltd. |
3/4/5
13D/G
10%+ Owner
|
11%
from 13D/G
|
$945,450
5,500,000 shares
|
— | 24 Jun 2026 |
| Apple Association 1st Nongae |
13D/G
Nongae Apple Association 1st
|
5.7%
|
$7,673,400
1,470,000 shares
|
$0 | 30 Apr 2025 |
| Peony Association 1st Red |
13D/G
Red Peony Association 1st
|
5.7%
|
$7,673,400
1,470,000 shares
|
$0 | 30 Apr 2025 |
| INTRACOASTAL CAPITAL, LLC |
13D/G
Mitchell P. Kopin
|
5%
|
$1,487,437
2,065,885 shares
|
$0 | 17 Feb 2026 |
| CITADEL ADVISORS LLC |
13F
Company
|
1%
|
$116,465
677,518 shares
|
— | 31 Mar 2026 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
Forms 3/4/5 flow
Insider trading overview
Insider buy and sell flow is broadly balanced over the last 12 months. No Buy or Sell transactions have been reported since 16 Jul 2025.
Buys
$0
Insiders: 0
Sells
$0
Insiders: 0
Net
$0
Shares: 0
Window
Last 12 months
4 rolling buckets
Buy value
Sell value
Shares: 0
Shares: 0
| Window (months) | Buy shares | Sell shares | Buy value | Sell value | Net value |
|---|---|---|---|---|---|
| 0-3 | 0 | 0 | $0 | $0 | $0 |
| 3-6 | 0 | 0 | $0 | $0 | $0 |
| 6-9 | 0 | 0 | $0 | $0 | $0 |
| 9-12 | 0 | 0 | $0 | $0 | $0 |
Reporting owners
Insider holders from Forms 3/4/5
Showing 1-14 of 14 reporting-owner rows connected to Liminatus Pharma, Inc.. Open a relationship link for the CIK-to-CIK filing trail.
Rows
14
Largest Forms 3/4/5 holder
Chris Kim
Net 12M change
$0
Latest report
02 Jul 2026
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Valuation | Report Date |
|---|---|---|---|---|---|---|
| Chris Kim | Chief Executive Officer, Director, 10%+ Owner | $69,466,653 | Mixed | 02 Jul 2026 | ||
| Valetudo Therapeutics LLC | 10%+ Owner | $69,466,653 | Mixed | 02 Jul 2026 | ||
| Iris Acquisition Holdings LLC | 10%+ Owner | $45,885,000 | Mixed | 30 Apr 2025 | ||
| KH Feelux Co., Ltd | 10%+ Owner | $20,880,000 | Mixed | 30 Apr 2025 | ||
| Ewon Comfortech Co., Ltd. | 10%+ Owner | $945,450 | Median | 24 Jun 2026 | ||
| Scott Dam | Chief Financial Officer | Mixed | 30 Apr 2025 | |||
| Beom K. Choi | Chief Technology Officer | Mixed | 30 Apr 2025 | |||
| Sang-Jin Daniel Lee | Head of Research & Development | Mixed | 30 Apr 2025 | |||
| Ji Yeon Baek | Director | Mixed | 30 Apr 2025 | |||
| Eun Sook Lee | Director | Mixed | 30 Apr 2025 | |||
| Nicholas Fernandez | Director | Mixed | 30 Apr 2025 | |||
| Byong C. Yoo | Chief Science Officer | Mixed | 30 Apr 2025 | |||
| Richard JaiHwan Baek | Director | Mixed | 10 Jul 2025 | |||
| II Philip Wayne Lemons | Director | Mixed | 10 Jul 2025 |
Recent insider transactions for Liminatus Pharma, Inc.
Showing up to 300 recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | SEC-reported value | SEC-reported price | Shares | Shares owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| Valetudo Therapeutics LLC | LIMN | Common Stock, par value $0.0001 per share | Other | 192.1% | 3,448,926 | 5,244,351 | 02 Jul 2026 | Direct | ||
| Valetudo Therapeutics LLC | LIMN | Common Stock, par value $0.0001 per share | Other | 192.1% | 3,448,926 | 5,244,351 | 02 Jul 2026 | Direct | ||
| Valetudo Therapeutics LLC | LIMN | Common Stock, par value $0.0001 per share | Other | -70.9% | -4,373,603 | 1,795,803 | 24 Jun 2026 | Direct | ||
| Valetudo Therapeutics LLC | LIMN | Common Stock, par value $0.0001 per share | Other | -70.9% | -4,373,603 | 1,795,803 | 24 Jun 2026 | Direct |
* marks a reported price that did not pass the local price check.